JP2000500737A - 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品 - Google Patents

腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品

Info

Publication number
JP2000500737A
JP2000500737A JP9513269A JP51326997A JP2000500737A JP 2000500737 A JP2000500737 A JP 2000500737A JP 9513269 A JP9513269 A JP 9513269A JP 51326997 A JP51326997 A JP 51326997A JP 2000500737 A JP2000500737 A JP 2000500737A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
group
tnf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9513269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500737A5 (enExample
Inventor
ショーアミ，エサー
ガリレイ，ルス
メコラム，ラファエル
Original Assignee
イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ filed Critical イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ
Publication of JP2000500737A publication Critical patent/JP2000500737A/ja
Publication of JP2000500737A5 publication Critical patent/JP2000500737A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP9513269A 1995-09-11 1996-09-10 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品 Ceased JP2000500737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals
IL115245 1995-09-11
PCT/IL1996/000108 WO1997011668A2 (en) 1995-09-11 1996-09-10 TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS

Publications (2)

Publication Number Publication Date
JP2000500737A true JP2000500737A (ja) 2000-01-25
JP2000500737A5 JP2000500737A5 (enExample) 2004-08-12

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9513269A Ceased JP2000500737A (ja) 1995-09-11 1996-09-10 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品

Country Status (9)

Country Link
US (3) US5932610A (enExample)
EP (1) EP0876143B1 (enExample)
JP (1) JP2000500737A (enExample)
AT (1) ATE331503T1 (enExample)
AU (1) AU708886B2 (enExample)
CA (1) CA2231764A1 (enExample)
DE (1) DE69636308T2 (enExample)
IL (1) IL115245A (enExample)
WO (1) WO1997011668A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
HUP0203437A3 (en) 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
AU5969101A (en) 2000-05-12 2001-11-26 Genzyme Corp Modulators of tnf-alpha signaling
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
WO2002026728A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
US7057076B2 (en) * 2001-07-13 2006-06-06 University Of Connecticut Bicyclic and tricyclic cannabinoids
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
JP4928079B2 (ja) * 2002-11-21 2012-05-09 ジェンザイム・コーポレーション 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
JP2006509038A (ja) * 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
NZ594077A (en) * 2005-09-29 2013-02-22 Albany Molecular Res Inc Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
US6545041B2 (en) 2003-04-08
IL115245A (en) 2002-12-01
ATE331503T1 (de) 2006-07-15
AU708886B2 (en) 1999-08-12
US20020049245A1 (en) 2002-04-25
DE69636308T2 (de) 2007-05-31
WO1997011668A2 (en) 1997-04-03
CA2231764A1 (en) 1997-04-03
EP0876143A2 (en) 1998-11-11
IL115245A0 (en) 1995-12-31
DE69636308D1 (de) 2006-08-10
US5932610A (en) 1999-08-03
EP0876143B1 (en) 2006-06-28
WO1997011668A3 (en) 1997-05-15
EP0876143A4 (en) 2001-06-27
AU6942096A (en) 1997-04-17
US6331560B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
JP2000500737A (ja) 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
JP2012505257A (ja) 多発性硬化症治療のための組成物および方法
JP2004518653A (ja) 不安障害を治療する方法
JP2002527474A (ja) 躁病および双極性障害の治療法
CA2781436A1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
JPS59501459A (ja) カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法
US20080182892A1 (en) Treatment of interstitial cystitis using (6aR, 10aR)-delta-8-tetrahydrocannabinol-11-oic acids
BG62120B1 (bg) Фармацевтични състави за ректално приложение наалкилсулфонамиди - агонисти на 5-нт1
EA001325B1 (ru) Способы лечения и профилактики интерстициального цистита
KR20210047887A (ko) 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
KR100297212B1 (ko) 직장투여용조성물
JPH0768235B2 (ja) Ｎｍｄａ遮断薬剤組成物
JP2003530350A (ja) 外傷性脳損傷及びその他のニューロン障害治療用医薬
EP2146713B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
WO2017133518A1 (zh) 淫羊藿苷及其衍生物在制备用于预防和治疗精神障碍的药物中的用途
CN112043700A (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
EP2556049A1 (en) Methods and compositions for the treatment of irritable bowel syndrome
JP2003504396A (ja) マクロライド化合物の新規用途
JPH11513386A (ja) β−受容体遮断薬とオピオイドとの新規な組合せ物
JP2004083553A (ja) ギンコライド−ａを含有する抗不安剤
EP4277614A1 (en) Compositions and methods for inducing defecation
JPH0892089A (ja) ドライバジャイナ治療剤
JP2002114681A (ja) 勃起不全治療剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080610

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20081028